Oragenics Activates All Australian Sites for Phase IIa Trial of ONP-002 in Concussion

Oragenics Inc. (NYSE American: OGEN) announced the activation of all three sites in its Australian Phase IIa clinical trial of ONP-002 for mild traumatic brain injury (concussion), following the activation of Royal Adelaide Hospital. The company reported that no serious adverse events have been observed in dosed participants to date, and it continues to target a Phase IIa data readout in the fourth quarter of 2026. This milestone marks a significant step forward in the development of ONP-002, which is delivered via the company's proprietary intranasal delivery technology.

In addition to the trial progress, Oragenics disclosed that it submitted a Type B meeting request to the U.S. Food and Drug Administration (FDA) on June 26 to obtain guidance on its planned U.S. clinical development program for ONP-002. The company noted that this meeting supports its goal of submitting an Investigational New Drug (IND) application in the fourth quarter of 2026. The FDA's feedback will be crucial in shaping the design and requirements for future U.S. trials, potentially accelerating the path to market for this novel therapy.

ONP-002 is being developed as a first-in-class treatment for concussion and mild traumatic brain injury, addressing a significant unmet medical need. Current treatment options are limited, and a therapy that could reduce symptoms and improve recovery outcomes would have substantial implications for patients, athletes, and military personnel. The intranasal delivery platform used for ONP-002 allows for direct brain targeting, potentially enhancing efficacy and reducing systemic side effects. Oragenics believes this technology has broader applications across other neurological conditions, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders.

The Australian trial's progress and the proactive engagement with the FDA demonstrate Oragenics' commitment to advancing ONP-002 through clinical development. With no serious adverse events reported so far, the safety profile appears encouraging, though the full data readout will provide more comprehensive insights. The company's timeline, targeting a Phase IIa readout and an IND submission in late 2026, suggests a focused and methodical approach to bringing this therapy to patients. For more details, the full press release is available at https://ibn.fm/Yye2E.

Oragenics, Inc. is a clinical-stage biotechnology company developing brain-targeted therapeutics through its proprietary intranasal delivery technology. The company is working on advancing ONP-002 as a potential first-in-class treatment for concussion and mild traumatic brain injury, with ongoing clinical trials in Australia and planned U.S. Phase 2b trials to follow. More information can be found at oragenics.com.